Valsartan amlodipine capsule and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of valsartan and amlodipine capsules and amlodipine besylate, which is applied in the technical field of improvement of oral solid preparations, and can solve the problems of slow release, inability to solve disintegration and dissolution, etc.
Inactive Publication Date: 2011-04-27
林海平
View PDF5 Cites 12 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, when valsartan and amlodipine besylate are mixed in a certain proportion, especially in high doses, and then packed into capsules, after the capsule shell disintegrates in the dissolution me
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0032] Valsartan 160g
[0033] Amlodipine besylate 13.86g
[0034] Microcrystalline Cellulose 106g
[0035] Crospovidone 50g
[0036] Silica 0.65g
[0037]
[0038] Makes 1000 capsules
[0039] Amlodipine besylate, crospovidone, microcrystalline cellulose, valsartan, and silicon dioxide in the prescribed amount are added to the mixer in sequence, fully mixed, and filled into capsules.
Embodiment 2
[0041] Valsartan 160g
[0042] Amlodipine besylate 6.93g
[0043]Microcrystalline Cellulose 50g
[0044] Crospovidone 40g
[0045] Silica 0.26g
[0046]
[0047] Makes 1000 capsules
[0048] Amlodipine besylate, crospovidone, microcrystalline cellulose, valsartan, and silicon dioxide in the prescribed amount are added to the mixer in sequence, fully mixed, and filled into capsules.
Embodiment 3
[0050] Valsartan 320g
[0051] Amlodipine besylate (calculated as amlodipine) 13.86g
[0052] Microcrystalline Cellulose 60g
[0053] Crospovidone 80g
[0054] Silica 1.0g
[0055]
[0056] Makes 1000 capsules
[0057] Amlodipine besylate, crospovidone, microcrystalline cellulose, valsartan, and silicon dioxide in the prescribed amount are added to the mixer in sequence, fully mixed, and filled into capsules.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a capsule containing valsartan and amlodipine besylate, which is prepared from high-dose valsartan and amlodipine besylate, disintegrating agent crospovidone, filling agent microcrystalline cellulose and lubricating agent silicondioxide. The problem that the compound preparation contianing a high dose of valsartan and amlodipine besylate is not easy to disintegrate and dissolve is solved by adopting the conventional process and equipment of powder mixing and direct capsule filling without using special equipment and the bilayer tablet process.
Description
Technical field: [0001] The invention relates to an oral pharmaceutical composition containing valsartan and amlodipine besylate, and relates to an improved technology for an oral solid preparation of a compound preparation of valsartan and amlodipine besylate. Background technique: [0002] The incidence of hypertension remains high, and there are about one billion hypertensive patients in the world. Blood pressure cannot be controlled within the range of the target value, which can induce cardiovascular disease, kidney disease and metabolic disease. Controlling blood pressure levels can effectively reduce the incidence and mortality of cardiovascular events. Although various antihypertensive drugs are currently on the market, 40% to 80% of hypertensive patients still cannot achieve the prescribed blood pressure control target value, mainly due to poor patient compliance or insufficient medication. Current treatment guidelines recommend the use of compound preparations to...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more